Pharmacy Bulk Package - Not for Direct Injection

**Fustella**


**Quality Assurance**

AGIN

Giomeron 250 50 ml

I colori su questa prova sono approssimativi, a base acqua CMYK. Definizione e colori non riflettono il risultato finale della produzione stampata.

---

**PROHANCE MULTIPACK (gadoteridol)**

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

**Pharmacy Bulk Package - Not for Direct Infusion**

**DOSAGE FORMS AND STRENGTHS**

**Contraindications**

**Nephrogenic Systemic Fibrosis (NSF)**

**Warnings and Precautions**

**Hypersensitivity Reactions**

**Lesions in the Head and Neck in Adults**

**Pregnancy**

**Geriatric Use**

**Patient Counseling Information**

**Pharmacokinetics**

**Drug Interactions**

**Adverse Reactions**

**Special Populations**

**Pediatric Use**

**Information for Patients**

**Overdosage**

**Overdosage**

**Clinical Trials Experience**

---

**Initial US Approval: 2003**

---

**PROHANCE MULTIPACK**:

**Pharmacy Bulk Package - Not for Direct Infusion**

**DOSAGE FORMS AND STRENGTHS**

**Contraindications**

**Nephrogenic Systemic Fibrosis (NSF)**

**Warnings and Precautions**

**Hypersensitivity Reactions**

**Lesions in the Head and Neck in Adults**

**Pregnancy**

**Geriatric Use**

**Patient Counseling Information**

**Pharmacokinetics**

**Drug Interactions**

**Adverse Reactions**

**Special Populations**

**Pediatric Use**

**Information for Patients**

**Overdosage**

**Clinical Trials Experience**

---

**PROHANCE MULTIPACK**:

**Pharmacy Bulk Package - Not for Direct Infusion**

**DOSAGE FORMS AND STRENGTHS**

**Contraindications**

**Nephrogenic Systemic Fibrosis (NSF)**

**Warnings and Precautions**

**Hypersensitivity Reactions**

**Lesions in the Head and Neck in Adults**

**Pregnancy**

**Geriatric Use**

**Patient Counseling Information**

**Pharmacokinetics**

**Drug Interactions**

**Adverse Reactions**

**Special Populations**

**Pediatric Use**

**Information for Patients**

**Overdosage**

**Clinical Trials Experience**

---

**PROHANCE MULTIPACK**:

**Pharmacy Bulk Package - Not for Direct Infusion**

**DOSAGE FORMS AND STRENGTHS**

**Contraindications**

**Nephrogenic Systemic Fibrosis (NSF)**

**Warnings and Precautions**

**Hypersensitivity Reactions**

**Lesions in the Head and Neck in Adults**

**Pregnancy**

**Geriatric Use**

**Patient Counseling Information**

**Pharmacokinetics**

**Drug Interactions**

**Adverse Reactions**

**Special Populations**

**Pediatric Use**

**Information for Patients**

**Overdosage**

**Clinical Trials Experience**

---

**PROHANCE MULTIPACK**:

**Pharmacy Bulk Package - Not for Direct Infusion**

**DOSAGE FORMS AND STRENGTHS**

**Contraindications**

**Nephrogenic Systemic Fibrosis (NSF)**

**Warnings and Precautions**

**Hypersensitivity Reactions**

**Lesions in the Head and Neck in Adults**

**Pregnancy**

**Geriatric Use**

**Patient Counseling Information**

**Pharmacokinetics**

**Drug Interactions**

**Adverse Reactions**

**Special Populations**

**Pediatric Use**

**Information for Patients**

**Overdosage**

**Clinical Trials Experience**

---

**PROHANCE MULTIPACK**:

**Pharmacy Bulk Package - Not for Direct Infusion**

**DOSAGE FORMS AND STRENGTHS**

**Contraindications**

**Nephrogenic Systemic Fibrosis (NSF)**

**Warnings and Precautions**

**Hypersensitivity Reactions**

**Lesions in the Head and Neck in Adults**

**Pregnancy**

**Geriatric Use**

**Patient Counseling Information**

**Pharmacokinetics**

**Drug Interactions**

**Adverse Reactions**

**Special Populations**

**Pediatric Use**

**Information for Patients**

**Overdosage**

**Clinical Trials Experience**
Adverse events have been observed in patients with renal impairment, with the frequency of events increasing with decreasing levels of renal function. These patients may have impaired tubular excretion of ProHance, leading to prolonged pharmacokinetics.

In patients with severe renal impairment (creatinine clearance < 25 mL/min), ProHance should be administered with caution.

ProHance was evaluated in a multicenter clinical trial of 103 pediatric patients who were a mean age of 8.7 years with an age range of 2 to 20 years. Of these 103 patients, 74% were Caucasian, 11% Black, 12% Hispanic, 2% Asian, and 2% other.

ProHance was evaluated in two multicenter trials of 310 evaluable patients, and 75-82% of the scans were enhanced, 45-48% of the scans provided additional information, and 20-30% of the patients had an additional scan performed.

The results of the non-contrast and gadoteridol MRI scans were compared. In this database, approximately 49 girls) had a mean age of 8.7 years with an age range of 2 to 20 years. Of these 103 patients, 74% were Caucasian, 11% Black, 12% Hispanic, 2% Asian, and 2% other.

ProHance was evaluated in a multicenter clinical trial of 103 pediatric patients who were a mean age of 8.7 years with an age range of 2 to 20 years. Of these 103 patients, 74% were Caucasian, 11% Black, 12% Hispanic, 2% Asian, and 2% other.

ProHance was evaluated in a multicenter clinical trial of 103 pediatric patients who were a mean age of 8.7 years with an age range of 2 to 20 years. Of these 103 patients, 74% were Caucasian, 11% Black, 12% Hispanic, 2% Asian, and 2% other.

ProHance was evaluated in a multicenter clinical trial of 103 pediatric patients who were a mean age of 8.7 years with an age range of 2 to 20 years. Of these 103 patients, 74% were Caucasian, 11% Black, 12% Hispanic, 2% Asian, and 2% other.
**MEDICATION GUIDE**  
**PROHANCE®** *(prō- han(t)s)*  
(Gadoteridol)  
Injection for intravenous use

### What is PROHANCE?
- PROHANCE is a prescription medicine called a gadolinium-based contrast agent (GBCA). PROHANCE, like other GBCAs, is used with a magnetic resonance imaging (MRI) scanner.
- An MRI exam with a GBCA, including PROHANCE, helps your doctor to see problems better than an MRI exam without a GBCA.
- Your doctor has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam.

### What is the most important information I should know about PROHANCE?
- PROHANCE contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years).
- It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.
- Rarely, patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium.
- There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance. Gadolinium stays in the body the least after Dotarem, Gadavist, or ProHance.
- People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.
- Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive PROHANCE.

### Do not receive PROHANCE if you have had a severe allergic reaction to PROHANCE.

Before receiving PROHANCE, tell your healthcare provider about all your medical conditions, including if you:
- have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.
- are pregnant or plan to become pregnant. It is not known if PROHANCE can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as PROHANCE is received during pregnancy
- have kidney problems, diabetes, or high blood pressure
- have had an allergic reaction to dyes (contrast agents) including GBCAs

### What are the possible side effects of PROHANCE?
- See “What is the most important information I should know about PROHANCE?”
- Allergic reactions. PROHANCE can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.

The most common side effects of PROHANCE include: nausea, taste perversion, headache, feeling hot, or burning at the injection site.

### General information about the safe and effective use of PROHANCE.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about PROHANCE that is written for health professionals.

### What are the ingredients in PROHANCE?
- **Active ingredient:** gadoteridol
- **Inactive ingredients:** calteridol calcium, tromethamine

Manufactured by: BIPSO GmbH-78224 Singen (Germany)  
Manufactured for: Bracco Diagnostics Inc., Monroe Township, NJ 08831  
US Patent No. 5,474,756; 5,846,519; and 6,143,274.

For more information, go to www.imaging.bracco.com or call 1-800-257-5181.

This Medication Guide has been approved by the U.S. Food and Drug Administration  
Issued: 04/2018  
COEB503